Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q3 FY21 Earnings Presentation
24 slides from Cohance Lifesciences's earnings presentation, February 2021
Slide 1: Suven Pharma Earnings Presentation Q3 FY21
SUVEN PHARMA Earnings Presentation Q3 FY21
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q3FY21 3
Slide 4: Operation & Financial Performance Q3 FY21
Operation & Financial Performance Q3 FY21 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other Ser vices 223.58 486.01 196.53 68.09 377.4 53.09 216.96 33.19 68.73 23.25 78.85 34.8 Q3FY20 Q3FY21 9MFY20 9MFY21 Q3FY20 Q3FY21 9MFY20 9MFY21 Q3FY20 Q3FY21 9MFY20 9MFY21 Note: Figures in Rs. Crore 5
Slide 6: Financial Snapshot
Financial Snapshot Q3FY21 9MFY21 Growth in Growth in Growth in Revenue EBITDA PAT 52.39% 69.31% 96.21% 15.06% 12.30% 14.99% 6
Slide 7: Key Ratios Q3FY21
Key Ratios Q3FY21 Q3FY20 EBIT to EBITDA to PAT to Income Income Income 47.98% 51.11% 40.61% 43.00% 46.00% 31.54% 7
Slide 8: Key Ratios 9MFY21
Key Ratios 9MFY21 9MFY20 EBIT to EBITDA to PAT to Income Income Income 44.17% 47.25% 36.67% 45.90% 48.40% 36.69% 8
Slide 9: Financials Q3FY21
Financials Q3FY21 Revenue EBIDTA PAT EPS 2,798 1,136 1,430 4.5 2,377 1,836 989 741 2.9 RUPEES MN RUPEES MN RUPEES MN 845 RUPEES 579 2.3 Q3FY20 Q2FY21 Q3FY21 Q3FY20 Q2FY21 Q3FY21 Q3FY20 Q2FY21 Q3FY21 Q3FY20 Q2FY21 Q3FY21 9
Slide 10: Financials 9MFY21
Financials 9MFY21 Revenue EBIDTA PAT EPS 7,615 3,597 11.0 2,792 6,618 3,203 9.5 2,428 RUPEES MN RUPEES MN RUPEES MN RUPEES 9MFY20 9MFY21 9MFY20 9MFY21 9MFY20 9MFY21 9MFY20 9MFY21 10
Slide 11: Financials Q3FY21 margins
Financials Q3FY21 EBITDA Margin (%) PAT Margin (%) 51% 46% 42% 41% 32% 31% Q3FY20 Q2FY21 Q3FY21 Q3FY20 Q2FY21 Q3FY21 11
Slide 12: Financials 9MFY21 margins
Financials 9MFY21 EBITDA Margin (%) PAT Margin (%) 48% 47% 37% 37% 9MFY20 9MFY21 9MFY20 9MFY21 12
Slide 13: Financial Table – Q3 FY21
Financial Table – Q3 FY21 Quarter ended Period ended Year ended 31-Dec-20 30-Sep-20 31-Dec-19 31-Dec-20 31-Dec-19 31-Mar-20 Revenue 2,797.76 2,377.45 1,835.94 7,614.93 6,618.03 8,519.07 EBITDA 1,429.98 988.50 844.59 3,596.95 3,203.03 4,029.10 EBITDA Margin 51.11% 41.58% 46.00% 47.24% 48.40% 47.30% E
Slide 14: Company Background
Company Background PHARMA
Slide 15: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 15
Slide 16: Brief Profile
Brief Profile BUSINESS OVERVIEW KEY STRENGTHS o Integrated CDMO company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Consolidated Revenues, EBITDA and process research & across the entire CDMO Adj. PAT of Rs 2440 Mn, Rs 1281 Mn dev
Slide 17: Suven is an integrated Contract Development and Manufacturing Operations company
Suven is an integrated Contract Development and Manufacturing Operations company Suven Life Sciences provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since o
Slide 18: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 18 18
Slide 19: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 19
Slide 20: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities research capabilities Present across the to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 20
Slide 21: Business Drivers: Execution Capabilities
Business Drivers Execution Capabilities Over 90% of Working with revenues from innovator companies regulated in developed markets markets having stringent Long term regulations – commercial supply reflection of our opportunity with research skills Repeat business the launch of owing to long product
Slide 22: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 23: Contact
Contact For queries and requests, please contact: Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Email: info@suvenpharm.com For more info: www.suvenpharm.com # 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA. Gavin Desa / Risha
Slide 24: Thank You
Thank You 6 SUVEN PHARMA
Suven Pharmaceuticals — Q3 FY21 Earnings Presentation on 6ix